• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Protein Kinase Inhibitor
    24 Drugs classified under this drug class

    All the Drug Class Drugs

    Filter by letter: ALL A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
    partial basket chart

    Protein Kinase Inhibitor. Everolimus 2.5, 5, 10 mg.
    TABS: 30 x 2.5 mg, 5 mg, 10 mg. Tmt. to
    be initiated by physician experienced
    in the use of anticancer ther. Orally
    once dly., at the same time ev. d. See
    Tmt. pts. with advanced ren. cell
    carcinoma aft. fail. of tmt. with sunitinib or
    sorafenib. Tmt. pts. with SEGA assoc. with
    tuberous sclerosis complex who req. ther.
    but not candidates for curative surg.
    resect. Effect. based on analys. of change
    in SEGA vol. Clin. benefit in improvement
    dis.-relat,. sympts/increase in overall
    survival has not been demonstrat. Tmt.
    progress. neuroendocrine tumors
    pancreat. origin in pts. with unresect.,
    locally advanced/metastat. dis. Safety/
    effectivenss in tmt. carcinoid tumors have
    not been established. Tmt. of horm.
    receptor-pos., HER2/neu neg. advanc.
    breast canc. in combi. with exemestane in
    postmen. women w/o symp. visceral dis.
    after recur. or progress. following nonsteroid.
    aromat. inh.. Tmt. of adult pts.
    with renal angiomyolipoma and tuberous
    sclerosis comp., nor req. immediate surg.
    Effectiv. of the drug in tmt. of renal
    angiomyolipoma based on an analysis of
    durable obj. respons. in pts. treat. for a
    median of 8.3 mnths. Further follow-up of
    pts. is req. to determine long-term
    Tmt. of unresect., local. advanc. /metastat.,
    well-different. (Grade 1/ Grade 2) nonfunct.
    neuroendocrine tumour. of GI or
    lung origin in adults with progress. dis.
    C/I: Hypersens. to active substances,
    other rapamycin derivs., excips.

    partial basket chart

    Protein Kinase Inhibitor. Alectinib 150 mg.
    HARD CAPS.:240.
    600 mg (4×150 mg caps.) ×2/d with food , max. dly. dose of 1200 mg). See lit.
    Tmt. of pts. with ALK posit., local. advanc. or metast. non-small cell lung cancer (NSCLC) who progres. on or are intolerant to crizotinib. Alectinib as monother. - for the 1st -line tmt. of adult pts. with anaplastic lymphoma kinase (ALK)-posit. advanc. non-small cell lung cancer. (NSCLC).
    C/I: Hypersens.

    Alunbrig® 30, 90 mg
    partial basket chart
    Alunbrig® 30, 90 mg

    Protein Kinase Inhibitor. Brigatinib 30 mg, 90 mg.
    F.C. TABS.: 30. The recom. dose regimen for is: 90 mg×1/d for the first 7 days;
    If 90 mg is tolerat. during the first 7 d, incr. the dose to 180 mg ×1/d.
    Admin. will cont. until dis. progres. or unaccept. toxicity.
    If Brigatinib is interrupt. for 14 d. or longer for reasons other than ADR's, resume tmt. at 90 mg ×1/d for 7 d. before incr. to the prev. tolerated dose.
    Tmt. of pts. with anaplastic lymphoma kinase (ALK)-positive metastat. non-small cell lung cancer (NSCLC) who have progres. on or are intolerant to crizotinib.
    C/I: Hypersens.

    partial basket chart

    Protein Kinase Inhibitor. Erdafitinib 3,4,5 mg.
    F.C. TABS.:56,84. The recom. init. dose of is 8 mg (2tabs ×1/d), with a dose incr. to 9 mg (three 3 mg tabs.) once dly. based on serum phosphate (PO4) levels and tolerabil. at 14 to 21 d. with or without food If vomit. occurs any time after taking Balversa, the next dose should be taken the next day. Tmt. should cont. until dis. progres.or unaccept. toxicity occurs. See lit.
    Tmt. of adult pts. with locally advanc. or metastat. urothelial carcinoma (mUC), that has: Suscept. FGFR3 or FGFR2 genet. alterations, and Progres. during or follow. at least one line of prior platinum-contain. chemother., includ. within 12 mnths. of neoadjuvant /adjuvant platinum-contain. chemother.
    C/I: Hypersens.

    partial basket chart

    Protein Kinase Inhibitor. Bosutinib 100, 400, 500 mg.
    F.C. TABS.: 28 x 100 mg, 400 mg, 500 mg. Newly-diagn. CP Ph+ CML: The recommend. dose is 400×1/d.
    CP, AP, or BP Ph+ CML with resistance or intoler.to prior ther.: The recomm. dose is 500 mg×1/d. Doses greater than 600 mg/day have not been studied and therefore should not be given. See lit.
    Tmt. of adult pts. withNewly-diagn. chron. phase (CP) Philadelphia chromos.-posit. chron. myelogenous leukaem. (Ph+ CML).
    Chron. phase (CP), acceler. phase (AP), and blast phase (BP) Philadelphia chromos. posit. chron. myelogenous leukaem. (Ph+ CML) prev. treated with one/more tyrosine kinase inhib.(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropr. tmt. options.
    C/I: Hypersens., Hepatic impair.

    partial basket chart

    Protein Kinase Inhibitor. Cobimetinib Hemifumarate 20 mg.
    F.C. TABS.:63.
    60 mg (3 tabs. of 20 mg) once dly., taken on a 28 day cycle. 
    21 consecutive d.  (1st  -21st day -tmt. period); follow.by a 7-day break (22nd -28th –tmt. break).  Each subseq. tmt. cycle should start after the 7-day tmt. break has elapsed. See lit.
    Indicat.  for use in comb.  with vemurafenib for the tmt. of adult pts. with unresectab. or metastat. melanoma with a BRAF V600 mutation.
    C/I: Hypersens.